Livforsakringsbolaget Skandia Omsesidigt Buys 9,200 Shares of Amgen Inc. $AMGN

Key Points

• Livforsakringsbolaget Skandia Omsesidigt increased its stake in Amgen Inc. by 19.6%, owning 56,218 shares valued at approximately $15.7 million as of the latest SEC filing.
• Amgen reported a quarterly earnings per share (EPS) of $6.02, exceeding analysts' estimates of $5.28 and showcasing a 9.4% revenue increase year-over-year.
• The company announced a quarterly dividend of $2.38 per share, yielding about 3.5%, while the current payout ratio stands at 77.84%.

Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 19.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,218 shares of the medical research company's stock after purchasing an additional 9,200 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt's holdings in Amgen were worth $15,689,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after buying an additional 3,653,205 shares during the last quarter. Nuveen LLC bought a new stake in shares of Amgen during the 1st quarter worth $688,868,000. Two Sigma Advisers LP grew its position in Amgen by 96.9% in the fourth quarter. Two Sigma Advisers LP now owns 1,545,600 shares of the medical research company's stock worth $402,845,000 after acquiring an additional 760,700 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Amgen in the fourth quarter valued at $193,339,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Amgen by 15.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,128,328 shares of the medical research company's stock valued at $1,336,647,000 after purchasing an additional 685,785 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Up 0.4%

Shares of NASDAQ AMGN traded up $1.12 during mid-day trading on Thursday, hitting $275.83. The stock had a trading volume of 3,322,465 shares, compared to its average volume of 2,767,839. The business has a 50 day moving average price of $291.25 and a two-hundred day moving average price of $291.09. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $339.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market cap of $148.50 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion during the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter in the prior year, the company posted $4.97 EPS. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date was Friday, August 22nd. Amgen's payout ratio is currently 77.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on AMGN shares. Piper Sandler upped their price objective on Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a report on Monday, August 25th. Cantor Fitzgerald restated a "neutral" rating and issued a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Bank of America upped their target price on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research note on Wednesday, July 23rd. Raymond James Financial started coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a "market perform" rating on the stock. Finally, William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $304.43.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.76% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.